GAL, galanin and GMAP prepropeptide, 51083

N. diseases: 226; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4330043
Disease: Gingival Squamous Cell Carcinoma
Gingival Squamous Cell Carcinoma 		0.010 AlteredExpression disease BEFREE Gal-1 expression in GSCC was significantly correlated with T cell infiltration (p=0.036), and apoptosis of CD3+ and CD8+ T cells (p<0.001). 28108653 2017
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.010 Biomarker disease BEFREE Galanin is a neuroendocrine factor responsible for regulation of physiological responses, such as feeding behavior and mood, and has been implicated in the development of fatty liver disease, although its role in biliary hyperplasia is unknown. 28196718 2017
CUI: C0948008
Disease: Ischemic stroke
Ischemic stroke 		0.010 Biomarker disease BEFREE Galanin (GAL) plays key role in many pathophysiological processes, but its role in ischemic stroke remains unclear. 28203483 2017
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.400 Biomarker disease BEFREE Galanin and its receptors appear to play key roles in depression-like behavior, and effects on hippocampal neurogenesis are relevant to pharmacological strategies for treating depression, which in part appear to rely on restoring altered neurogenesis. 28431685 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.400 Biomarker disease BEFREE Galanin and its receptors appear to play key roles in depression-like behavior, and effects on hippocampal neurogenesis are relevant to pharmacological strategies for treating depression, which in part appear to rely on restoring altered neurogenesis. 28431685 2017
CUI: C0344315
Disease: Depressed mood
Depressed mood 		0.100 Biomarker phenotype BEFREE Galanin and its receptors appear to play key roles in depression-like behavior, and effects on hippocampal neurogenesis are relevant to pharmacological strategies for treating depression, which in part appear to rely on restoring altered neurogenesis. 28431685 2017
CUI: C1333064
Disease: Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma 		0.020 AlteredExpression disease BEFREE Gal-1 can be secreted from cells by an unknown mechanism, and levels in blood samples were associated with high tumor burden and worse disease state in cHL and CLL patients. 28435287 2017
CUI: C2347747
Disease: Adult Classical Hodgkin Lymphoma
Adult Classical Hodgkin Lymphoma 		0.020 AlteredExpression disease BEFREE Gal-1 can be secreted from cells by an unknown mechanism, and levels in blood samples were associated with high tumor burden and worse disease state in cHL and CLL patients. 28435287 2017
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.020 AlteredExpression disease BEFREE Gal-1 can be secreted from cells by an unknown mechanism, and levels in blood samples were associated with high tumor burden and worse disease state in cHL and CLL patients. 28435287 2017
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.030 Biomarker disease BEFREE Gal-1 knock-down reduces macrophages' polarization switch from M1 (pro-inflammatory) to M2 (anti-inflammatory) during GBM progression. 28450700 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.070 Biomarker group BEFREE Gal-1 may offer an additional therapeutic target linking anti-angiogenesis and immune checkpoint blockade.<i>Cancer </i>. 28473314 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.060 Biomarker group BEFREE Gal-1 may offer an additional therapeutic target linking anti-angiogenesis and immune checkpoint blockade.<i>Cancer </i>. 28473314 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Galanin is a neuropeptide with a widespread distribution throughout the nervous and endocrine systems, and recent studies have shown an anti-proliferative effect of galanin on several types of tumors. 28525358 2017
CUI: C0262385
Disease: Autonomic nervous system imbalance
Autonomic nervous system imbalance 		0.010 Biomarker disease BEFREE Galanin, a cotransmitter similar to neuropeptide Y (NPY), aggravates autonomic imbalance in systolic heart failure (HF) by attenuating vagal tonus after burst sympathetic activity. 28811392 2017
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.400 AlteredExpression disease BEFREE Galanin, a peptide expressed in mammalian brain regions, has been implicated in anxiety and depression. 29499176 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.400 AlteredExpression disease BEFREE Galanin, a peptide expressed in mammalian brain regions, has been implicated in anxiety and depression. 29499176 2018
CUI: C0344315
Disease: Depressed mood
Depressed mood 		0.100 AlteredExpression phenotype BEFREE Galanin, a peptide expressed in mammalian brain regions, has been implicated in anxiety and depression. 29499176 2018
CUI: C0003467
Disease: Anxiety
Anxiety 		0.090 Biomarker disease BEFREE Galanin regulates the release of neurotransmitters in some brain regions related to anxiety, including the hippocampus. 29499176 2018
CUI: C0003469
Disease: Anxiety Disorders
Anxiety Disorders 		0.090 Biomarker group BEFREE Galanin regulates the release of neurotransmitters in some brain regions related to anxiety, including the hippocampus. 29499176 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.040 Biomarker phenotype BEFREE Gal-1 knockdown significantly inhibited CRPC cells' growth, anchorage-independent growth, migration, and invasion through the suppression of androgen receptor (AR) and Akt signaling. 29666302 2018
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.070 Biomarker disease BEFREE Galanin and galanin receptors (GALRs) are well established as molecular biomarkers to predict the survival rate and risk of recurrence of head and neck squamous cell carcinoma. 29805635 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.040 AlteredExpression phenotype BEFREE Gal-1 expression and VM in primary GC tissue were associated with tumor size, differentiation, depth of tumor invasion, stage, lymph node metastases, and tumor emboli in microvessels (all, <i>P</i> < 0.05). 29881296 2018
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.030 AlteredExpression disease BEFREE Gal-1 expression was positively associated with VM in primary GC tissue. 29881296 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.030 AlteredExpression disease BEFREE Gal-1 expression was positively associated with VM in primary GC tissue. 29881296 2018
CUI: C0013274
Disease: Patent ductus arteriosus
Patent ductus arteriosus 		0.010 Biomarker disease BEFREE Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. 30250644 2018